60 related articles for article (PubMed ID: 24342289)
1. Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms.
Bellizzi AM
Semin Diagn Pathol; 2013 Nov; 30(4):329-61. PubMed ID: 24342289
[TBL] [Abstract][Full Text] [Related]
2. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers.
Gologan A; Sepulveda AR
Clin Lab Med; 2005 Mar; 25(1):179-96. PubMed ID: 15749237
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
5. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
Green RC; Parfrey PS; Woods MO; Younghusband HB
J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in gastroenterology: between hope and hype comes histopathology.
Jankowski JA; Odze RD
Am J Gastroenterol; 2009 May; 104(5):1093-6. PubMed ID: 19417749
[TBL] [Abstract][Full Text] [Related]
9. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
Miettinen M; Wang ZF; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013
[TBL] [Abstract][Full Text] [Related]
10. Screening in GI Cancers: The Role of Genetics.
Stoffel EM
J Clin Oncol; 2015 Jun; 33(16):1721-8. PubMed ID: 25918283
[TBL] [Abstract][Full Text] [Related]
11. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
[TBL] [Abstract][Full Text] [Related]
12. Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply?
D'Arcy C; Wen YH; Stadler ZK; Brogi E; Shia J
Am J Surg Pathol; 2011 Nov; 35(11):1743-8. PubMed ID: 21997695
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors.
Daum O; Grossmann P; Vanecek T; Sima R; Mukensnabl P; Michal M
Ann Diagn Pathol; 2007 Feb; 11(1):27-33. PubMed ID: 17240304
[TBL] [Abstract][Full Text] [Related]
14. Contribution of DOG1 expression to the diagnosis of gastrointestinal stromal tumors.
Kara T; Serinsoz E; Arpaci RB; Gubur O; Orekici G; Ata A; Colak T; Arican A
Pathol Res Pract; 2013 Jul; 209(7):413-7. PubMed ID: 23722018
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
17. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics.
Orta L; Klimstra DS; Qin J; Mecca P; Tang LH; Busam KJ; Shia J
Am J Surg Pathol; 2009 Jun; 33(6):934-44. PubMed ID: 19342947
[TBL] [Abstract][Full Text] [Related]
18. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.
Baraniskin A; Van Laethem JL; Wyrwicz L; Guller U; Wasan HS; Matysiak-Budnik T; Gruenberger T; Ducreux M; Carneiro F; Van Cutsem E; Seufferlein T; Schmiegel W
Eur J Cancer; 2017 Nov; 86():305-317. PubMed ID: 29065378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
